What happens after your Mounjaro pen finishes its 4 doses?

Does finishing a pen always mean going up a dose?

Not necessarily. The 4-week pen cycle and the titration schedule happen to line up, but they are not the same thing. The licensed titration pathway for tirzepatide starts at 2.5 mg for approximately four weeks, then increases in 2.5 mg steps, each lasting roughly four weeks, toward whatever maintenance dose works for you. The NHS patient information on tirzepatide describes this escalation clearly.

What that means in practice: finishing your fourth dose is the natural moment to discuss the next strength with your prescriber. But if nausea, vomiting or other gastrointestinal symptoms were difficult to manage, a sensible prescriber will often recommend repeating the same dose for another four weeks before stepping up. There is no clinical rule that says the fifth injection must be stronger than the fourth. Tolerability matters as much as the schedule.

One thing our prescribers hear fairly often: patients who order a repeat slightly late because the four-week run lands over a bank holiday or at the end of the month when budgets are tight. If that gap between pens is longer than seven days, mention it at your next review, continuity does affect how your body is responding. You can read more about what changes across the whole treatment journey on our Mounjaro overview page.

What should you actually do when the pen runs out?

First, do not attempt to get additional doses from a used pen. Mounjaro KwikPens are designed to deliver exactly four injections. After the fourth, the pen is finished and should be disposed of in a sharps container as instructed in the Patient Information Leaflet.

Second, contact your prescribing service before you run out rather than after. For patients at nume (at the pharmacy behind the service) every repeat order goes through a clinical review by a GPhC-registered prescriber before dispatch. That review confirms which strength is right for your next four weeks. Evidence of how you have been getting on, including any side effects, feeds into that decision. If you are new to treatment and want to understand what has typically changed at each pen, the dose-by-dose breakdown covers this in more detail.

Third, if you experienced any side effects that concerned you during the first four weeks, note them down. Specifics help: when they started, how long they lasted, whether they were improving by dose three or four. If you want a closer look at how things typically feel toward the end of a pen, our page on what to expect after 2 doses of Mounjaro and the follow-up page on how things tend to shift after 3 doses can help you put your own experience in context. That information shapes what your prescriber recommends next.

What if side effects were rough on the 2.5 mg pen?

The 2.5 mg starting dose exists specifically to let your body adjust to the medicine, not to produce meaningful weight loss at that stage. Gastrointestinal effects (nausea in particular) are most common in the first week or two after starting or after a dose increase. Many people find they settle considerably by weeks three and four.

If they did not settle, or if they were severe enough to affect daily life, that is important clinical information. Dose increases are never mandatory at the four-week mark. Your prescriber can hold you at 2.5 mg for a further four weeks, and there is published guidance (referenced in the BNF entry for tirzepatide) supporting a flexible titration approach based on individual tolerability. Reducing the dose is also an option if a higher strength was too much; guidance on managing that is covered separately on our dose-reduction and side effects page.

The 5 mg pen is the next step for most people after the starter pen. A detailed look at what that strength involves is on the Mounjaro 5 mg page if that is where you are headed.

What does a responsible prescriber check before approving the next pen?

Before a new pen is issued (whether the same strength or the next one) a prescriber should be looking at more than just the date. At a minimum: whether you have been tolerating the current dose, whether there are any new symptoms that warrant attention, and whether your weight trend is heading in the right direction over time.

The MHRA flagged in January 2026 that severe, persistent stomach pain radiating to the back can be a sign of pancreatitis, a known but uncommon risk with GLP-1 medicines. That is exactly the kind of symptom a prescriber needs to know about before approving the next dose. Yellow Card reporting at yellowcard.mhra.gov.uk is also available to patients who want to record a suspected side effect formally.

A genuine clinical review is not a formality. At nume, no repeat is approved by an algorithm, a named prescriber reads your answers. If you have questions about your specific situation or want guidance before ordering your next pen, speaking to our prescribers is the right place to start.